Arginine-rich cross-linking peptides with different SV40 nuclear localization signal content as vectors for intranuclear DNA delivery by Bogacheva, Mariia et al.
Gene	therapy	is	a	highly	promising	approach	to	cure	various	inherited	and	acquired	diseases.1,2	The	outcome	of	gene	therapy	greatly	depends	on	the	way	of	gene	delivery.	Because	of	high	transfection	efficacy
the	majority	of	gene	therapy	clinical	trials	known	so	far	used	viral-mediated	delivery.	However	non-viral	carriers	being	less	efficient	lack	immunogenic	and	cytotoxic	issues	are	more	safe	and	versatile	for	nucleic	acids
(NA)	compared	to	viral	delivery.
The	main	goal	of	non-viral	gene	delivery	studies	concerns	development	of	highly	efficient	vectors,	which	are	able	to	overcome	all	cellular	barriers	of	NA	transport.3	One	of	the	most	formidable	intracellular
barriers	for	DNA	transport	along	with	cellular	and	endosomal	membranes	is	a	nuclear	membrane,	which	controls	the	exchange	of	macromolecules	between	nucleus	and	cytoplasm	and	it	must	be	overcome	to	reach
expression	of	the	therapeutic	gene.	Direct	injection	of	plasmid	DNA	into	cell	nuclei	provide	up	to	50%	cells	expressed	transgenes,	while	their	amount	was	approximately	1%	if	plasmid	was	injected	into	cytoplasm.4
There	are	two	feasible	ways	to	penetrate	nuclear	membrane:	(I)	degraded	nuclear	envelope	during	mitosis	and	(II)	penetration	of	nuclear	membrane	through	the	pores	with	a	diameter	of	approximately	40 nm.5	The
latter	 represents	 an	 only	 available	way	 for	 nuclear	 internalization	 in	 non-dividing,	 slowly	 dividing	 and	post-mitotic	 cells.	 Import	 of	 large	molecules	 (>45 kDa)	 occurs	 by	means	 of	 special	 receptors	 –	 importins	 –
transport	proteins	of	nuclear	pore	complex	which	recognize	the	specific	sequence	–	nuclear	localization	signal	(NLS).6	Viral	NLS	of	SV40	large	T-antigen	(126PKKKRKV132)	attaches	to	importin-α	on	the	nuclear	envelope
surface	and	form	complex	with	importin-β	providing	intranuclear	transport.7	Direct	conjugation	of	NLS	to	DNA	is	inefficient,	but	nuclear	delivery	can	be	increased	by	NLS-modified	liposomes	and	polymers.8–10
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Abstract
The	major	barriers	 for	 intracellular	DNA	 transportation	by	cationic	polymers	are	 their	 toxicity,	poor	endosomal	escape	and	 inefficient	nuclear	uptake.	Therefore,	we	designed	novel	modular	peptide-based	carriers
modified	with	SV40	nuclear	localization	signal	(NLS).	Core	peptide	consists	of	arginine,	histidine	and	cysteine	residues	for	DNA	condensation,	endosomal	escape	promotion	and	interpeptide	cross-linking,	respectively.	We
investigated	three	polyplexes	with	different	NLS	content	(10 mol%,	50 mol%	and	90 mol%	of	SV40	NLS)	as	vectors	for	intranuclear	DNA	delivery.	All	carriers	tested	were	able	to	condense	DNA,	to	protect	it	from	DNAase	I	and
were	not	toxic	to	the	cells.	We	observed	that	cell	cycle	arrest	by	hydroxyurea	did	not	affect	transfection	efficacy	of	NLS-modified	carriers	which	we	confirmed	using	quantitative	confocal	microscopy	analysis.	Overall,	peptide
carrier	modified	with	90 mol%	 of	 SV40	NLS	 provided	 efficient	 transfection	 and	 nuclear	 uptake	 in	 non-dividing	 cells.	 Thus,	 incorporation	 of	NLS	 into	 arginine-rich	 cross-linking	 peptides	 is	 an	 adequate	 approach	 to	 the
development	of	efficient	intranuclear	gene	delivery	vehicles.
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Recently	we	developed	arginine-rich,	cysteine-flanked	peptide	R6	which	can	be	modified	with	certain	ligand	to	achieve	receptor-mediated	gene	and	siRNA	delivery.11–13	Oligoarginine	stretch	in	R6	sequence
promotes	effective	electrostatic	binding	of	DNA,	while	cysteine	residues	can	oxidize	to	disulfide	bonds	during	template	polymerization,	allowing	cross-linking	between	peptides	and	formation	of	stable	DNA/carrier
complexes.	Histidine	residues	provide	endosomal	escape	due	to	their	buffering	capacity.14,15
We	developed	multifunctional	peptide-based	non-viral	carrier	modified	with	NLS	of	SV40	large	T-antigen	through	the	two	molecules	of	ε-aminohexanoic	acid	spacer	(PKKKRKVG-Ahx-Ahx-CHRRRRRRHC)	and
designated	it	as	NL	peptide	module.	Combination	of	NLS-modified	module	(NL)	and	unmodified	peptide	CHRRRRRRHC	(R6)	by	means	of	polymerization	on	DNA	template	resulted	in	three	carriers	with	different	NLS
content:	NL1	with	10 mol%,	NL2	with	50 mol%	and	NL3	with	90 mol%	of	NLS-modified	peptides	respectively.	The	aim	of	current	research	was	to	study	arginine-rich	cross-linking	peptides	with	different	SV40	NLS
content,	as	vectors	for	intranuclear	DNA	delivery.
R6	and	NL	peptides	were	synthesized	using	a	solid	phase	Boc-chemistry	by	NPF	Verta,	LLC	(Saint-Petersburg,	Russia)	(Table	1).	They	were	dissolved	in	0.1%	trifluoroacetic	acid	at	2 mg/ml	and	stored	at	−20 °C.
The	purity	of	 the	peptides	determined	by	high-performance	 liquid	chromatography	was	90–95%.	Polyethyleneimine	(branched	PEI	25 kDa;	Sigma)	was	used	as	at	0.9 mg/ml	 (pH	7.5).	We	used	pCMV-lacZ	plasmid
(pDNA)	with	β-galactosidase	gene	under	cytomegalovirus	promoter	control	(gift	from	Prof.	B.	Sholte,	Erasmus	University	Rotterdam,	the	Netherlands),	diluted	to	1 mg/ml	and	stored	at	−20 °C.	DNA/peptide	complexes
were	prepared	at	various	N/P	ratios	(peptide	nitrogen/DNA	phosphorus	ratio)	in	the	range	0.1–8	and	PEI	to	DNA	8:1.	pDNA	was	diluted	in	20 μg/ml	in	Hepes-buffered	mannitol	(HBM)	(5%	w/v	mannitol,	5 mM	Hepes,
pH	7.5).	Then	peptides	at	2 mg/ml	were	added	to	the	DNA	solution	and	vortexed.	Complexes	were	left	at	room	temperature	for	2 h	for	template	polymerization.	Template	polymerized	carriers	NL1,	NL2	and	NL3	were
obtained	by	mixing	solutions	of	NL	and	R6	peptides	before	the	addition	of	pDNA	(10 mol%	and	90 mol%;	50 mol%	and	50 mol%;	90 mol%	and	10 mol%,	respectively).	Peptide-DNA	binding	was	monitored	by	agarose	gel
retardation	and	the	ethidium	bromide	(EtBr)	fluorescence	quenching	assay.	Peptides’	ability	to	protect	DNA	from	endonuclease	degradation	was	checked	by	reaction	of	complexes	with	0.5	units	of	DNase	I	(Promega,
Madison,	WI,	USA)	for	30 min	at	37 °C.	Transfection	experiments	were	performed	in	human	cervical	carcinoma	(HeLa)	cell	line	(Institute	of	Cytology	RAS,	Saint-Petersburg,	Russia).	Cell	cycle	was	blocked	with	2.5 mM
hydroxyurea	(HU)	(Sigma).	Before	transfection	culture	medium	was	replaced	with	serum-free	medium.	Complexes	were	incubated	with	cells	for	4 h.	The	β-galactosidase	activity	 in	cell	extracts	was	measured	with
MUG	reaction	solution	 (Sigma)	using	a	Wallac	1420D	scanning	multilabel	counter	 (355 nm/460 nm).	β-galactosidase	activity	 (mU)	was	determined	by	means	of	calibration	curve	using	diluted	β-galactosidase	with
known	 activity	 (Promega).	 The	 reporter	 gene	 expression	 was	 normalized	 by	 the	 total	 protein	 concentration	 of	 the	 cell	 extracts,	 measured	 with	 Bradford	 reagent	 (Helicon,	 Russia).	 For	 intranuclear	 delivery
visualization	pDNA	was	mixed	with	intercalating	dye	YOYO-1	iodide	(491 nm/509 nm)	–	1 mM	solution	in	DMSO	(Invitrogen)	in	ratio	1	molecule	of	dye	per	50	base	pairs.	Then	transfections	with	or	without	HU	were
carried	out	and	cell	nuclei	were	stained	with	the	Hoechst	33258	(Sigma-Aldrich,	USA)	(0.5 mkg/ml)	in	Dulbecco	buffer	(pH	7.2	–	7.4).	DNA	was	visualized	in	24 h	after	transfection	by	means	of	the	Olympus	FluoView™
FV1000	confocal	laser	scanning	microscope.	Quantitative	data	are	presented	as	the	percentages	of	transfected	nuclei	containing	fluorescent	signal	of	YOYO-1.	Mean	values	were	presented	and	standard	deviations	of
triplicate	samples	were	counted	for	600	nuclei	per	sample.	To	confirm	the	intranuclear	localization	in	the	3D	images,	4-sectioned	images	were	overlapped	into	a	single	image.	The	nuclei	were	considered	positive	if
YOYO-1-generated	fluorescent	signal	was	present	inside	nucleus	after	3D	reconstruction	procedure.	The	cytotoxicity	of	complexes	was	evaluated	using	Alamar	blue	assay	(BioSource	International,	USA).	Statistically
significant	differences	were	analyzed	by	Mann–Whitney	U	test	and	by	Student’s	t-test,	using	Instat	(GraphPad	Software	Inc.,	USA).	p < 0.05	was	considered	statistically	significant.
Table	1	Composition	of	modular	peptide	carriers.
Name Formula
Control	peptide	R6 CHRRRRRRHC
Large	SV40	Tag	–	modified	peptide	module	NL PKKKRKVG-Ahx-Ahx-CHRRRRRRHC
NL	peptide	module-consisting	carriers NL1 10 mol%	NL + 90 mol%	R6
NL2 50 mol%	NL + 50 mol%	R6
NL3 90 mol%	NL + 10 mol%	R6
Control	carrier	PEI Branched	PEI	25 kDa
Table	1	demonstrates	the	list	of	carriers,	which	we	used	in	the	present	study.	Our	group	previously	developed	R6	peptide	which	we	used	as	a	control.11	NL1	carrier	comprises	the	PKKKRKVG	motif	and	the
DNA-binding	sequence	of	R6	(CHRRRRRRHC),	separated	from	each	other	with	two	ε-aminocaproic	acid	molecules	 (Ahx).	NL1	 is	a	combination	of	10 mol%	of	NL	and	90 mol%	of	R6	peptide,	NL2	carrier	 includes
50 mol%	of	NL	peptide	and	50 mol%	of	R6,	NL3	peptide	is	a	combination	of	90 mol%	of	NL	and	10 mol%	of	R6	peptide.
We	studied	DNA-binding	capacity	of	the	carriers	by	means	of	ethidium	bromide	fluorescence	quenching	assay.	EtBr	releases	out	of	DNA	during	complex	formation	which	causes	fluorescence	intensity	decrease.
Free	DNA	was	used	as	a	control	with	maximal	fluorescence	taken	as	100%.	We	observed	clear	difference	in	DNA	condensation	by	peptides	with	different	NLS	content.	Complete	complex	formation	by	unmodified	R6
peptide	and	NL1	carrier	started	at	1.5:1	peptide/DNA	charge	ratio,	whereas	for	NL2	and	NL3	carriers	it	began	at	1:1	(Fig.	1).	The	results	of	this	assay	generally	agreed	with	gel	retardation	test	(data	not	shown).	Thus
it	was	concluded	 that	modification	of	R6	peptide	with	NLS	module	 improves	 its	DNA-condensation	properties,	due	 to	 the	 increasing	of	 the	carrier’s	positive	charge.	Previously	Siprashvili	with	co-authors	clearly
showed	that	increase	of	cationic	residues	number	in	peptide	carriers	leads	to	augmentation	of	their	DNA-condensing	properties.16
An	 important	property	of	 synthetic	DNA-carriers	 is	 ability	 to	protect	DNA	 from	endonuclease	degradation.17	Degree	of	DNA	condensation	by	 cationic	peptides	directly	 correlates	with	 its	 susceptibility	 to
nuclease	degradation.18	Protective	properties	of	the	carriers	were	estimated	by	DNase	I	protection	assay.	The	DNA	integrity	was	compared	with	this	one	of	native	DNA	and	DNase	I	treated	DNA.	We	demonstrated	that
NL2	and	NL3	protected	DNA	from	degradation	at	N/P	ratio	0.5:1,	while	NL1	partly	protected	it	from	DNase	I	at	1.5:1	N/P	ratio	similarly	to	unmodified	carrier	R6	(Fig.	2).	Thereby	NL2	and	NL3	carriers	possess	the
most	effective	DNA-protection	properties,	suggesting	that	at	least	50 mol%	content	of	NLS-containing	module	in	the	carrier	is	required	for	optimal	DNA	protection.	Improved	DNA	protection	by	means	of	carriers	with
higher	NLS-content	could	be	explained	by	steric	hindrances	caused	due	to	presence	of	NLS	and	Ahx-linker.
Fig.	1	DNA	binding	studies	by	ethidium	bromide	exclusion	from	complexes	of	DNA	and	NL1,	NL2,	NL3	and	R6	carriers.	Values	are	means ± standard	deviation	of	the	mean	of	triplicates.
Fig.	2	DNase	I	protective	ability	of	DNA-complexes	formed	with	R6	(a),	NL1	(b),	NL2	(c)	and	NL3	(d)	carriers.	Underlined	charge	ratio	indicates	beginning	of	DNA	protection.	C-“naked”	plasmid	DNA	treated	with	DNase	I;	C+	untreated	plasmid	DNA.
Cytotoxicity	of	peptide/DNA	complexes	after	transfection	in	vitro	was	evaluated	at	three	charge	ratios	(4:1,	8:1	and	12:1)	using	the	Alamar	blue	assay.	We	observed	significantly	higher	degree	of	cell	viability
after	transfection	with	DNA/peptide	complexes	at	4:1	and	8:1	N/P	ratios	compared	to	the	PEI/DNA	in	HeLa	cells	(Fig.	3).	These	results	demonstrated	that	studied	peptides	possessed	less	cytotoxicity	compared	to	PEI.
Also	there	was	no	statistically	significant	difference	in	cytotoxicity	between	native	DNA	and	complexes	of	NL1,	NL2,	NL3	and	DNA	at	4:1	and	8:1	N/P	ratios	in	HeLa	cells.	These	results	match	previous	data	on	role	of
disulfide	bonds	reduction	in	decrease	of	the	carrier	toxicity.11,19
In	the	present	study,	a	non-dividing	cell	model	was	made	by	synchronization	of	the	HeLa	cell	cycle	at	G1	phase	via	treatment	with	2.5 mM	of	hydroxyurea	(HU)	which	affects	over	90%	of	cells.20	No	differences
in	 transfection	efficacy	 in	HeLa	cells	between	dividing	cells	and	arrested	cells	were	 found,	whereas	efficacy	of	PEI/DNA	and	R6/DNA	complexes	was	significantly	decreased	after	HU	treatment	 (Fig.	 4).	 Thereby,
increasing	of	the	complexes’	transfection	efficacy	in	non-dividing	cells	can	be	associated	with	the	presence	of	specific	NLS,	which	gives	them	an	opportunity	to	overcome	nuclear	envelope	barrier	and	provide	the
same	level	of	gene	delivery,	which	is	typical	for	dividing	cells.	It	is	known,	that	the	presence	of	an	NLS	peptide	increases	number	of	transfected	cells	in	dividing	and	non-dividing	cells.21
With	a	confocal	microscopy	we	demonstrated	localization	of	plasmid	DNA	in	HeLa	cells	after	transfection	and	estimated	efficacy	of	intranuclear	delivery.	YOYO-1	–	labeled	pDNA	in	complexes	with	the	NL1,
NL2	and	NL3	at	N/P	ratio	of	8:1	was	studied.	R6/DNA	complexes	at	the	same	N/P	ratio	and	naked	DNA	served	as	a	control.	The	cells	treated	with	naked	DNA	had	negligible	green	fluorescence	(data	not	shown),
whereas	those	treated	with	peptide/DNA	complexes	displayed	obvious	intracellular	green	fluorescence.	DNA	delivered	by	R6	and	NL1	peptides	localized	mainly	in	cytoplasm	and	perinuclear	region,	indicating	low
transfection	efficacy	(Fig.	5a,	b,	c,	d).	However	NL2	and	NL3	peptides	provided	more	efficient	pDNA	delivery	and	promoted	its	preferable	localization	inside	the	nuclei	(Fig.	5f,	g,	h,	e).	3D	reconstruction	of	the	pDNA-
positive	cells,	transfected	with	pDNA/peptide	complexes	allowed	us	to	identify	YOYO-1-positive	nuclei	and	to	distinguish	the	fluorescence	from	complexes	located	in	the	perinuclear	and	the	intranuclear	areas	(Fig.	5i,
j).	The	nuclear	uptake	rate	of	pDNA	was	assessed	by	confocal	microscopy	image	analysis	followed	by	quantification	of	YOYO-1-positive	nuclei	(Fig.	6).
Fig.	3	Cytotoxicity	evaluation	of	peptide/DNA	complexes	by	means	of	Alamar	Blue	assay.	Values	are	means ± standard	deviation	of	the	mean	of	triplicates.
Fig.	4	Transfection	efficacy	evaluation.	The	HeLa	cell	line	was	transfected	with	NL1/DNA,	NL2/DNA,	NL3/DNA,	R6/DNA	complexes	at	charge	ratios	4:1	and	8:1,	PEI/DNA	complexes	at	charge	ratio	8:1	and	pCMV	lacZ	plasmid	alone.	Reporter	lacZ	gene
expression	is	given	as	milliunits	(mU)	per	milligram	of	total	protein.	Values	are	means ± standard	deviation	of	the	mean	of	triplicates.	Asterisk	indicates	p < 0.05	compared	with	cells	without	hydroxyurea	(HU)	treatment.
Fig.	5	Intranuclear	uptake	evaluation.	Intracellular	localization	of	YOYO-1-labeled	pCMV	lacZ	plasmid	in	HU-treated	(b,	d,	g,	e)	and	untreated	(a,	c,	f,	h)	HeLa	cells	after	delivery	by	R6/DNA	(a,	b),	NL1/DNA	(c,	d),	NL2/DNA	(f,	g)	and	NL3/DNA	(h,	e)
complexes	at	charge	ratio	8:1;	perinuclear	and	intranuclear	localization	(arrows)	of	YOYO-1-labeled	pCMV	lacZ	plasmid	after	delivery	by	R6/DNA	(i)	and	NL3/DNA	(j)	complexes	at	charge	ratio	8:1	in	the	3D	images	of	HeLa	cells;	bar	scale	represents	10 µm.
We	found	that	cells	treated	with	NL1	and	R6	polyplexes	demonstrated	35.2%	and	24%	of	YOYO-1-positive	nuclei,	whereas	the	amounts	of	transfected	nuclei	dropped	down	to	14.1%	and	12.4%,	respectively,
after	HU-mediated	cell	cycle	blockage	(Fig.	6).	Meanwhile,	according	to	quantitative	analysis	of	positively	transfected	nuclei	the	efficacy	of	DNA	delivery	with	NL2	and	NL3	carriers	remained	the	same	irrespective	of
HU	treatment.	It	has	been	found	that	NL2	and	NL3	polyplexes	provided	intranuclear	DNA	delivery	into	29.6%	and	26%	of	nuclei	without	HU	treatment.	In	cycle	arrested	cells	efficacy	of	intranuclear	DNA	delivery
mediated	by	NL2	and	NL3	carriers	dropped	insignificantly	(21.6%	and	23%	of	nuclei,	respectively)	(Fig.	6).	Thus,	confocal	microscopy	analysis	confirmed	improved	transfection	activity	due	to	the	increased	pDNA
intranuclear	delivery	by	means	of	SV40	NLS-modified	carriers.
In	the	present	study	we	designed	novel	transfection	enhancing	cross-linked	peptide-based	carriers	by	conjugation	of	NLS	to	arginine-rich	module,	which	increase	intranuclear	DNA	delivery	without	obvious
cytotoxicity.	We	assume	that	pDNA	is	not	fully	released	from	the	polyplexes	before	reaching	nucleus.	Actually,	the	disassembly	of	the	polyplexes	is	the	final	requirement	for	the	transcription	machinery	to	access	pDNA
for	efficient	transfection.	Although	the	interaction	of	polyamine	gene	vectors	with	intracellular	RNA	leads	to	the	dissociation	of	pDNA-carrier	complexes,	it	is	generally	accepted	that	at	least	part	of	the	polyplexes
localize	 intact	 to	 the	 nucleus,	where	 they	 presumably	 undergo	 dissociation.22,23	 Interaction	 of	 R6/DNA	 polyplexes	with	 the	 polyanions	 has	 been	 studied	 previously	 and	 it	 has	 been	 shown	 that	 R6	 peptide-based
polyplexes	are	not	susceptible	to	relaxation	by	polyanions.11	Thus,	it	can	be	suggested	that	NL	peptide-based	polyplexes	will	also	be	stable	in	an	intracellular	environment	and	will	not	be	completely	destroyed	when
interacting	with	RNA.	Also	it	should	be	noted	that	in	confocal	images	the	polyplexes	were	found	to	be	accumulated	in	cytoplasm	and	in	cell	nuclei	as	bright	green	dots	(fluorescence	from	YOYO-1	iodide-labeled	pDNA)
and	they	have	particle	shapes,	meaning	that	pDNA	was	still	condensed	with	the	peptide	carriers	(Fig.	5).	Thus,	it	can	be	assumed	that	pDNA	should	be	at	least	partly	bound	by	cationic	NLS-modified	peptides	used	in
our	study	as	carriers	for	intranuclear	delivery.
Also	we	showed	that	an	increase	in	content	of	NLS-conjugated	modules	improves	DNA	condensation	and	protection	properties	of	the	carriers.	Although	the	difference	between	NL	and	R6	polyplexes	can	be
seen	only	at	N/P	ratio	range	1–2	this	finding	may	provide	insights	into	transfection	and	nuclear	translocation	abilities	of	the	polyplexes.	Previously	it	has	been	shown	that	at	N/P	ratio	of	about	2,	cationic	polymer
molecules	completely	neutralize	DNA,	but	addition	of	more	polymer	to	this	neutral	core	 leads	to	the	formation	of	a	shell	of	extra	carrier	molecules	around	the	core	that	results	 in	 formation	of	positively	charged
polyplexes	with	their	highest	gene	transfer	activity.24	In	our	study	we	used	for	transfection	N/P	ratios	≥4	and	it	can	be	suggested	that	NL2	and	NL3	polyplexes	may	differ	from	NL1	and	R6	polyplexes	in	transfection
properties	because	their	neutral	cores	are	formed	at	different	N/P	ratios	(Figs.	1,	2).
According	to	obtained	results	modular	carrier	NL3	with	90 mol%	of	SV40	NLS-modifed	peptide	provided	the	most	efficient	transfection	and	nuclear	uptake	by	non-dividing	cells.	Our	study	proves	the	efficiency
of	cross-linking	peptide	modification	with	nuclear	localization	signal	for	the	gene	delivery	into	non-dividing	cells.
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